Progress on apatinib for solid tumors
JIANG Chang
MIAO Yuqing
WANG Zhan
WANG Jiejun
Abstract：Angiogenesis play an important role in the process of cell growth,and it is one of the basic characteristics of malignant tumors.So,antiangiogenesis is an effective way to anti-tumor.Apatinib is a novel small-molecule vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor.Through specific inhibition of vascular endothelial cells factor-2 tyrosine kinase activity,apatinib plays antiangiogenic and antitumor roles.Apatinib has demonstrated encouraging anticancer activity across a broad range of malignancies,including gastric cancer,breast cancer,non-small cell lung cancer,hepatocarcinoma and soft tissue tumor etc.This paper will make a review of clinical trials of apatinib to some solid tumors and provides reference for clinical practice in therapeutic options for cancer patients.
Keywords：Gastric cancerLung cancerBreast cancerApatinibVEGFR-2
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 281-284 )